2024MAY10: Our hosting provider is experiencing intermittent networking issues. We apologize for any inconvenience.

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

PKM2 diverts glycolytic flux in dependence on mitochondrial one-carbon cycle.

Cell reports | 2024

Modeling tumor metabolism in vitro remains challenging. Here, we used galactose as an in vitro tool compound to mimic glycolytic limitation. In contrast to the established idea that high glycolytic flux reduces pyruvate kinase isozyme M2 (PKM2) activity to support anabolic processes, we have discovered that glycolytic limitation also affects PKM2 activity. Surprisingly, despite limited carbon availability and energetic stress, cells induce a near-complete block of PKM2 to divert carbons toward serine metabolism. Simultaneously, TCA cycle flux is sustained, and oxygen consumption is increased, supported by glutamine. Glutamine not only supports TCA cycle flux but also serine synthesis via distinct mechanisms that are directed through PKM2 inhibition. Finally, deleting mitochondrial one-carbon (1C) cycle reversed the PKM2 block, suggesting a potential formate-dependent crosstalk that coordinates mitochondrial 1C flux and cytosolic glycolysis to support cell survival and proliferation during nutrient-scarce conditions.

Pubmed ID: 38421868 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ALDH1L2 antibody (antibody)

RRID:AB_2878854

This polyclonal targets ALDH1L2

View all literature mentions

CD19-PE-Vio770 (antibody)

RRID:AB_2661118

This monoclonal targets CD19

View all literature mentions

PE anti-mouse CD5 (antibody)

RRID:AB_312737

This monoclonal targets CD5

View all literature mentions

β-Actin (8H10D10) Mouse mAb (antibody)

RRID:AB_2242334

This monoclonal targets beta-actin

View all literature mentions

MTHFD1L antibody (antibody)

RRID:AB_2250974

This polyclonal targets MTHFD1L

View all literature mentions

PCK2 Antibody (antibody)

RRID:AB_10836185

This polyclonal targets PCK2

View all literature mentions

Anti-ALDH1L2 antibody produced in rabbit (antibody)

RRID:AB_10795465

This polyclonal targets ALDH1L2 antibody produced in rabbit

View all literature mentions

MTHFD2 (D8W9U) Rabbit mAb (antibody)

RRID:AB_2799200

This monoclonal targets MTHFD2

View all literature mentions

AMPK alpha (D5A2) Rabbit mAb (antibody)

RRID:AB_10622186

This monoclonal targets AMPK alpha

View all literature mentions

MDA-MB-468 (cell line)

RRID:CVCL_0419

Cell line MDA-MB-468 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

LCSB Metabolomics and Lipidomics Platform Core Facility (access service resource)

RRID:SCR_024769

Metabolomics and Lipidomics Platform facilitates metabolism related research, serving researchers from academia to industry in Luxembourg and beyond. Specializes in analysis of small molecules within complex biological matrices. Analytical infrastructure and broad method portfolio accelerate scientific discoveries in the areas of biology and biomedicine.

View all literature mentions